androgen antagonists

Summary

Summary: Compounds which inhibit or antagonize the biosynthesis or actions of androgens.

Top Publications

  1. pmc Abiraterone and increased survival in metastatic prostate cancer
    Johann S de Bono
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 364:1995-2005. 2011
  2. ncbi Quality of life and satisfaction with outcome among prostate-cancer survivors
    Martin G Sanda
    Departments of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Harvard University, Boston, MA 02215, USA
    N Engl J Med 358:1250-61. 2008
  3. ncbi Molecular determinants of resistance to antiandrogen therapy
    Charlie D Chen
    Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Nat Med 10:33-9. 2004
  4. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
  5. ncbi Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:965-74. 2006
  6. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
  7. ncbi A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
    C W Gregory
    Laboratory for Reproductive Biology, Department of Pediatrics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Cancer Res 61:4315-9. 2001
  8. ncbi Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
  9. pmc Contemporary role of androgen deprivation therapy for prostate cancer
    Vincenzo Pagliarulo
    Department of Urology, Aldo Moro University, Bari, Italy
    Eur Urol 61:11-25. 2012
  10. ncbi Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2359-66. 2011

Research Grants

Detail Information

Publications288 found, 100 shown here

  1. pmc Abiraterone and increased survival in metastatic prostate cancer
    Johann S de Bono
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 364:1995-2005. 2011
    ..We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy...
  2. ncbi Quality of life and satisfaction with outcome among prostate-cancer survivors
    Martin G Sanda
    Departments of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Harvard University, Boston, MA 02215, USA
    N Engl J Med 358:1250-61. 2008
    ....
  3. ncbi Molecular determinants of resistance to antiandrogen therapy
    Charlie D Chen
    Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Nat Med 10:33-9. 2004
    ..These findings provide insight toward the design of new antiandrogens...
  4. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
    ..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
  5. ncbi Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:965-74. 2006
    ..For example, if the median follow-up is 5 years, control rates at 3 years should be cited. Retaining a strict version of the ASTRO definition would allow comparisons with a large existing body of literature...
  6. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
    ..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
  7. ncbi A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
    C W Gregory
    Laboratory for Reproductive Biology, Department of Pediatrics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Cancer Res 61:4315-9. 2001
    ..Furthermore, we provide a molecular basis for this activation and suggest a general mechanism for recurrent prostate cancer growth...
  8. ncbi Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
    ..To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial...
  9. pmc Contemporary role of androgen deprivation therapy for prostate cancer
    Vincenzo Pagliarulo
    Department of Urology, Aldo Moro University, Bari, Italy
    Eur Urol 61:11-25. 2012
    ..Given the mounting evidence for potentially life-threatening adverse effects with short- and long-term ADT, it is important to redefine the role of ADT for this disease...
  10. ncbi Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2359-66. 2011
    ....
  11. pmc Targeting the androgen receptor pathway in prostate cancer
    Yu Chen
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Opin Pharmacol 8:440-8. 2008
    ..Many of these strategies are currently being tested in clinical trials in CRPC...
  12. pmc Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
    Gerhardt Attard
    Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 27:3742-8. 2009
    ..Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis...
  13. ncbi Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer
    Timothy J Wilt
    University of Minnesota School of Medicine, Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research, Minneapolis, Minnesota 55417, USA
    Ann Intern Med 148:435-48. 2008
    ..The comparative effectiveness of localized prostate cancer treatments is largely unknown...
  14. ncbi Androgen receptor in prostate cancer
    Cynthia A Heinlein
    George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester, Rochester, NY 14642, USA
    Endocr Rev 25:276-308. 2004
    ..The inhibition of AR activity through mechanisms in addition to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression...
  15. ncbi Duration of androgen suppression in the treatment of prostate cancer
    Michel Bolla
    Centre Hospitalier Regional Universitaire de Grenoble, Grenoble, France
    N Engl J Med 360:2516-27. 2009
    ..We compared the use of radiotherapy plus short-term androgen suppression with the use of radiotherapy plus long-term androgen suppression in the treatment of locally advanced prostate cancer...
  16. ncbi Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy
    Edward M Messing
    Department of Urology, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Lancet Oncol 7:472-9. 2006
    ....
  17. ncbi Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
    Eric M Horwitz
    Fox Chase Cancer Center, Department of Radiation Oncology, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 26:2497-504. 2008
    ..To determine whether adding 2 years of androgen-deprivation therapy (ADT) improved outcome for patients electively treated with ADT before and during radiation therapy (RT)...
  18. pmc Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study
    Monique M Cherrier
    Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA
    BMC Cancer 10:1. 2010
    ..A common treatment option for men with prostate cancer is androgen deprivation therapy (ADT). However, men undergoing ADT may experience physical side effects, changes in quality of life and sometimes psychiatric and cognitive side effects...
  19. pmc Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system
    Z Culig
    Department of Urology, University of Innsbruck, Austria
    Br J Cancer 81:242-51. 1999
    ..These findings may have repercussions on the natural course of prostate cancer with androgen deprivation and on strategies of therapeutic intervention...
  20. pmc Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
    Yu Chen
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lancet Oncol 10:981-91. 2009
    ..Both agents are undergoing phase 3 testing. Here, we review the basic science and clinical development of these and other agents...
  21. pmc AR, the cell cycle, and prostate cancer
    Steven P Balk
    Cancer Biology Program Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Nucl Recept Signal 6:e001. 2008
    ..As will be discussed, discrete aberrations in this process can alter the proliferative response to androgen, and potentially subvert hormonal control of tumor progression...
  22. ncbi Radiotherapy and short-term androgen deprivation for localized prostate cancer
    Christopher U Jones
    Radiological Associates of Sacramento, Sacramento, CA 95816, USA
    N Engl J Med 365:107-18. 2011
    ..It is not known whether short-term androgen-deprivation therapy (ADT) before and during radiotherapy improves cancer control and overall survival among patients with early, localized prostate adenocarcinoma...
  23. pmc Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
    William P Harris
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA 98195, USA
    Nat Clin Pract Urol 6:76-85. 2009
    ....
  24. pmc Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Cancer Inst 102:39-46. 2010
    ..We evaluated the relationship between androgen deprivation therapy and incident diabetes and cardiovascular disease in men of all ages with prostate cancer...
  25. ncbi External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
    Michel Bolla
    Radiotherapy Department, University Hospital, Grenoble, France
    Lancet Oncol 11:1066-73. 2010
    ..In this report, we present the 10-year results...
  26. ncbi The current state of hormonal therapy for prostate cancer
    Beth A Hellerstedt
    Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, USA
    CA Cancer J Clin 52:154-79. 2002
    ..New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated. Prevention of the side effects of therapy has led to the development of alternative schedules and therapeutics...
  27. ncbi Vinclozolin and p,p'-DDE alter androgen-dependent gene expression: in vivo confirmation of an androgen receptor-mediated mechanism
    W R Kelce
    National Health and Environmental Effects Research Laboratory, U S Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
    Toxicol Appl Pharmacol 142:192-200. 1997
    ..Taken together, these data indicate that vinclozolin and p,p'-DDE act as antiandrogens in vivo by altering the expression of androgen-dependent genes...
  28. ncbi Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state
    H Murillo
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Endocrinology 142:4795-805. 2001
    ..Successful progression to the androgen-independent state in the LNCaP cell line model requires intact PI3K signaling...
  29. pmc Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, San Francisco, CA 94115, USA
    J Clin Oncol 28:1481-8. 2010
    ..This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CPRC with or without prior ketoconazole therapy...
  30. pmc Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression
    G B Baretton
    Institute of Pathology, Ludwig Maximilians University, Munich, Germany
    Br J Cancer 80:546-55. 1999
    ..This finding might be clinically useful for planning therapy in these patients...
  31. ncbi Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial
    James W Denham
    School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
    Lancet Oncol 12:451-9. 2011
    ..Here we report the 10-year results...
  32. ncbi Resistance exercise in men receiving androgen deprivation therapy for prostate cancer
    Roanne J Segal
    Department of Medical Oncology, Ottawa Regional Cancer Centre General Site, 503 Smyth Rd, Ottawa, Ontario K1H 1C4, Canada
    J Clin Oncol 21:1653-9. 2003
    ..These physical changes can negatively affect health-related quality of life. Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat...
  33. ncbi Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
    M E Taplin
    University of Massachusetts Cancer Center, Worcester 01655, USA
    Cancer Res 59:2511-5. 1999
    ..These findings demonstrate that AR mutations occur in response to strong selective pressure from flutamide treatment...
  34. ncbi Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects
    N E Skakkebaek
    Department of Growth and Reproduction, Copenhagen University Hospital, Copenhagen, Denmark
    Hum Reprod 16:972-8. 2001
    ..Otherwise, important biological information may be lost...
  35. ncbi Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden
    Mieke Van Hemelrijck
    King s College London, London, United Kingdom
    J Clin Oncol 28:3448-56. 2010
    ..Cardiovascular disease (CVD) is a potential adverse effect of endocrine treatment (ET) for prostate cancer (PC). We investigated absolute and relative CVD risk in 76,600 patients with PC undergoing ET, curative treatment, or surveillance...
  36. ncbi Androgen deprivation therapy for prostate cancer: current status and future prospects
    Hiroshi Miyamoto
    George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Prostate 61:332-53. 2004
    ..In order to improve overall survival, novel treatment strategies that prolong the androgen-dependent state and that are useful for androgen-independent disease based on specific molecular mechanisms need to be identified...
  37. ncbi Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
    James W Denham
    Newcastle Mater Hospital, Newcastle, New South Wales, Australia
    Lancet Oncol 6:841-50. 2005
    ..We did a large randomised controlled trial to determine whether 3 months or 6 months of androgen deprivation given before and during radiotherapy improves outcomes for patients with locally advanced prostate cancer...
  38. ncbi Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase
    V Uma Bai
    Vattikuti Urology Institute, Henry Ford Health Sciences Center, Detroit, Michigan, USA
    J Cell Physiol 204:381-7. 2005
    ..AR may play an important role in the onset of DNA synthesis in prostate cancer cells by regulating the expression and stability of Cdc6, which is critically required for the assembly of the pre-replication complex(pre-RC)...
  39. ncbi Cholesterol as a potential target for castration-resistant prostate cancer
    Alexis L Twiddy
    Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, The University of British Columbia, 2146 East Mall Avenue, Vancouver, British Columbia, Canada
    Pharm Res 28:423-37. 2011
    ..This review summarizes the implications of cholesterol dysregulation in CaP and particularly in the post-ADT castration-resistant state, as well as the potential implementation of novel therapies targeting these cholesterol sources...
  40. ncbi Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness
    Hideyuki Akaza
    Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
    Cancer Sci 102:51-6. 2011
    ....
  41. pmc Quality of life three years after diagnosis of localised prostate cancer: population based cohort study
    David P Smith
    Cancer Council, Kings Cross, New South Wales 1340, Australia
    BMJ 339:b4817. 2009
    ..To quantify the risk and severity of negative effects of treatment for localised prostate cancer on long term quality of life...
  42. ncbi A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer
    Carie Corner
    Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, UK
    Int J Radiat Oncol Biol Phys 72:441-6. 2008
    ..A Phase II dose escalation study has been undertaken to evaluate high-dose-rate brachytherapy (HDRBT) monotherapy for prostate cancer...
  43. ncbi Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection
    Thuy Vi V Nguyen
    University of Southern California, Davis School of Gerontology, 3715 McClintock Avenue, Los Angeles, CA 90089 0191, USA
    Endocrinology 148:2936-43. 2007
    ..These findings provide new insight into the agonist vs. antagonist properties of antiandrogens, information that will be crucial to understanding the neural implications of clinically used AR-modulating drugs...
  44. ncbi Antiandrogenic effects in male rats perinatally exposed to a mixture of di(2-ethylhexyl) phthalate and di(2-ethylhexyl) adipate
    Kirsten Jarfelt
    Danish Institute for Food and Veterinary Research, Mørkhøj Bygade 19, DK 2860 Søborg, Denmark
    Reprod Toxicol 19:505-15. 2005
    ..However, no combination effect was seen with respect to antiandrogenic effects, as males receiving DEHP in combination with DEHA did not exhibit more pronounced effects in the reproductive system than males receiving DEHP alone...
  45. ncbi Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial
    Nicolas Mottet
    Department of Urology, University Hospital, St Etienne, France
    Eur Urol 62:213-9. 2012
    ..Radiotherapy combined with androgen-deprivation therapy (ADT) is superior to radiotherapy alone in localised prostate cancer; however, data comparing ADT alone are somewhat limited...
  46. pmc A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
    J Shamash
    St Bartholomew s Hospital, 7th Floor, Gloucester House, Little Britain, UK
    Br J Cancer 104:620-8. 2011
    ....
  47. ncbi Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
    ..Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT...
  48. ncbi Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions
    Yasuo Yoshioka
    Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Int J Radiat Oncol Biol Phys 80:469-75. 2011
    ..To evaluate an extreme hypofractionation regimen with 54 Gy in nine fractions provided by high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer by reporting 5-year clinical results...
  49. pmc Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
    Patrick Royston
    MRC Clinical Trials, London NW1 2DA UK
    Trials 12:81. 2011
    ..Such trials can terminate at any of the intermediate stages or the final stage...
  50. ncbi The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide
    Alfred Hobisch
    Department of Urology, General Hospital Feldkirch, Feldkirch, Austria
    Prostate 66:413-20. 2006
    ..However, little attention has been paid to the androgen receptor-signaling pathway in the development of therapy resistance in patients who receive chronic treatment with a non-steroidal anti-androgen...
  51. ncbi Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure
    Alexandra J Stewart
    Brigham and Women s Hospital, Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 23:6556-60. 2005
    ..2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM)...
  52. ncbi Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy
    Bo Ying Bao
    Department of Pharmacy, China Medical University, Taichung, Taiwan
    Int J Cancer 130:876-84. 2012
    ....
  53. pmc Androgen deprivation and cognition in prostate cancer
    E Salminen
    Department of Oncology, Turku University Hospital, Kiinamyllynkatu 4 8, FIN 20520 Turku, Finland
    Br J Cancer 89:971-6. 2003
    ..These results have implications for counseling and psychosocial support of patients in the context of treatment options in PC...
  54. ncbi Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
    Maha Hussain
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 24:3984-90. 2006
    ..To establish whether absolute prostate-specific antigen (PSA) value after androgen deprivation (AD) is prognostic in metastatic (D2) prostate cancer (PCa)...
  55. pmc SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer
    Ming Yang
    Dana Farber Cancer Institute, Harvard Medical School, Dana 710B, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 29:2565-73. 2011
    ..We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT...
  56. ncbi Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells
    Julia T Arnold
    Endocrine Section, Laboratory of Clinical Investigation, Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, Maryland 20892 0933, USA
    Prostate 67:1152-62. 2007
    ..LNCaP and LAPC-4 prostate cancer cells were used to determine whether DHEA-modulated proliferation and prostate specific antigen (PSA) production were mediated via the androgen receptor (AR) and/or ERbeta...
  57. pmc An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy
    Christopher R Orr
    Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Biol Chem 285:35567-77. 2010
    ....
  58. ncbi Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
    William R Foster
    Department of Discovery Toxicology, Bristol Myers Squibb Co BMS, Princeton, New Jersey 08543, USA
    Prostate 71:480-8. 2011
    ..The failure to discover new AR antagonists has occurred in the face of continued research; to enable progress, a clear understanding of the reasons for failure is required...
  59. ncbi Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss
    D M Preston
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Prostate Cancer Prostatic Dis 5:304-10. 2002
    ..0019). The ADT group lumbar spine value was -0.2%+/-0.8 % and 1.1%+/-0.6% in the control group (P=0.079). Our data demonstrate greater rates of bone mineral density loss in men receiving androgen deprivation therapy for prostate cancer...
  60. ncbi Risk of fracture after androgen deprivation for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0562, USA
    N Engl J Med 352:154-64. 2005
    ..This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied...
  61. ncbi Influence of number of CAG repeats on local control in the RTOG 86-10 protocol
    May Abdel-Wahab
    Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL 33136, USA
    Am J Clin Oncol 29:14-20. 2006
    ..The purpose of this study was to determine if short-term androgen deprivation therapy (RT + HT) can improve outcome in patients with tumors with short CAG repeats (<19)...
  62. ncbi Androgen deprivation therapy for prostate cancer
    Nima Sharifi
    Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD 20892, USA
    JAMA 294:238-44. 2005
    ..Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease...
  63. ncbi Resistance training and reduction of treatment side effects in prostate cancer patients
    Daniel A Galvão
    School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia
    Med Sci Sports Exerc 38:2045-52. 2006
    ..To examine the effect of progressive resistance training on muscle function, functional performance, balance, body composition, and muscle thickness in men receiving androgen deprivation for prostate cancer...
  64. ncbi Androgen receptors in prostate cancer
    Z Culig
    Department of Urology, University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 9:155-70. 2002
    ..New experimental therapies for prostate cancer are aimed to down-regulate AR expression and to overcome difficulties which occur because of the acquisition of agonistic properties of commonly used antiandrogens...
  65. ncbi Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature
    Per Anders Abrahamsson
    Department of Urology, Lund University, Malmo University Hospital, S 224 01, Malmo, Sweden
    Eur Urol 57:49-59. 2010
    ..Intermittent androgen deprivation (IAD) alternates androgen blockade with treatment cessation to allow hormonal recovery between treatment cycles, thus potentially improving tolerability and QoL...
  66. pmc Chemistry and structural biology of androgen receptor
    Wenqing Gao
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Chem Rev 105:3352-70. 2005
  67. pmc Metabolic complications of androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 181:1998-2006; discussion 2007-8. 2009
    ....
  68. pmc Structural basis for antagonism and resistance of bicalutamide in prostate cancer
    Casey E Bohl
    Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 102:6201-6. 2005
    ..Knowledge of the binding mechanism for R-bicalutamide will provide molecular rationale for the development of new antiandrogens and selective AR modulators...
  69. ncbi Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells
    Giuseppe Pandini
    Dipartimento di Medicina Interna e di Medicina Specialistica, Cattedra di Endocrinologia, University of Catania, Ospedale Garibaldi, Catania, Italy
    Cancer Res 65:1849-57. 2005
    ..Anti-androgen therapy may be only partially effective, or almost ineffective, in blocking important biological effects of androgens, such as activation of the IGF system...
  70. pmc Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
    Alison H M Reid
    The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    J Clin Oncol 28:1489-95. 2010
    ..The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC)...
  71. ncbi Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor
    Liang Nian Song
    Department of Oncology, Lombardi Cancer Center, Georgetown University, 3800 Reservoir Road, Northwest, Washington, D C 20057, USA
    Mol Endocrinol 18:70-85. 2004
    ..Mifepristone also antagonized R1881 action on the growth of LNCaP prostate cancer cells...
  72. ncbi Androgen-mediated development in male rat offspring exposed to flutamide in utero: permanence and correlation of early postnatal changes in anogenital distance and nipple retention with malformations in androgen-dependent tissues
    B S McIntyre
    CIIT Centers for Health Research, Six Davis Drive, P. O. Box 12137, Research Triangle Park, NC 27709-2137, USA
    Toxicol Sci 62:236-49. 2001
    ..These data suggest that flutamide-mediated changes in AGD and nipple retention are not sensitive predictors of altered T-mediated development...
  73. ncbi Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy
    Bo Ying Bao
    Department of Pharmacy, China Medical University, Taichung, Taiwan
    Clin Cancer Res 17:928-36. 2011
    ..We hypothesized that genetic variations in miRNAs and miRNA target sites could be associated with the efficacy of androgen-deprivation therapy (ADT) in men with prostate cancer...
  74. pmc From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
    S Yeh
    George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and the Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Proc Natl Acad Sci U S A 96:5458-63. 1999
    ..Together, these data provide a novel pathway from HER2/Neu to AR transactivation, and they may represent one of the reasons for the PSA re-elevation and hormone resistance during androgen ablation therapy in prostate cancer patients...
  75. pmc Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
    Padraig Warde
    Princess Margaret Hospital, Toronto, Canada
    Lancet 378:2104-11. 2011
    ..Our aim was to compare outcomes in such patients with locally advanced prostate cancer...
  76. ncbi Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy
    C N Huang
    Department of Urology Cancer Center, Kaohsiung Medical University Hospital, Taiwan
    J Intern Med 271:499-509. 2012
    ..Therefore, we tested whether common single-nucleotide polymorphisms (SNPs) inside EREs are related to the clinical outcomes of androgen-deprivation therapy (ADT) in men with prostate cancer...
  77. ncbi Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
    Mary Ellen Taplin
    University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA
    J Clin Oncol 21:2673-8. 2003
    ..Bone marrow specimens containing prostate tumor were obtained from men undergoing antiandrogen withdrawal for AR sequence analysis and clinical correlation...
  78. ncbi Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy
    C N Huang
    Department of Urology, Kaohsiung Medical University Hospital, Taiwan
    Ann Oncol 23:707-13. 2012
    ..Our aim was to determine whether genetic variants in AREs are associated with clinical outcomes after androgen-deprivation therapy (ADT) in prostate cancer patients...
  79. ncbi A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists
    Vickie S Wilson
    U S Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Reproductive Toxicology Division, MD 72, Research Triangle Park, North Carolina 27711, USA
    Toxicol Sci 66:69-81. 2002
    ..In summary, we have developed a cell line that can be used to screen chemicals, not just for AR- but for GR-mediated activities as well...
  80. pmc Abnormalities of sexual development in male rats with in utero and lactational exposure to the antiandrogenic plasticizer Di(2-ethylhexyl) phthalate
    R W Moore
    School of Pharmacy, University of Wisconsin, 425 N Charter St, Madison, WI 53706, USA
    Environ Health Perspect 109:229-37. 2001
    ..These results suggest that DEHP acts partly by mechanisms distinct from those of other antiandrogens...
  81. pmc Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer
    Matthew R Smith
    Division of Hematology Oncology, Mallinckrodt General Clinical Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 71:318-22. 2008
    ..We also assessed the relationships among changes in adipocytokines, body composition, and insulin sensitivity...
  82. ncbi Impact of androgen deprivation therapy on cardiovascular disease and diabetes
    Shabbir M H Alibhai
    University Health Network, Room EN14 214, 200 Elizabeth St, Toronto, Ontario, Canada, M5G 2C4
    J Clin Oncol 27:3452-8. 2009
    ..CONCLUSION Continuous ADT use for at least 6 months in older men is associated with an increased risk of diabetes and fragility fracture but not AMI or sudden cardiac death...
  83. ncbi Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review
    Shabbir M H Alibhai
    Division of General Internal Medicine and Clinical Epidemiology, University Health Network, Toronto, Canada
    Crit Rev Oncol Hematol 60:201-15. 2006
    ..Further insight into adverse effects of ADT and strategies to minimize these adverse effects await data from ongoing studies...
  84. ncbi Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity
    John M Kokontis
    Ben May Institute for Cancer Research and the Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, Illinois 60637, USA
    Prostate 65:287-98. 2005
    ..Various studies have implicated the androgen receptor (AR) in the progression of androgen-dependent human prostate cancer cells to androgen-independent and androgen-insensitive phenotypes, but the exact role of AR in progression is unclear...
  85. ncbi Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor
    David Masiello
    Cancer Biology Program, Hematology Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Biol Chem 277:26321-6. 2002
    ..These results demonstrate that bicalutamide stimulates the assembly of a transcriptionally inactive AR on DNA and support altered coactivator (or corepressor) expression as a mechanism of bicalutamide-resistant androgen-independent PCa...
  86. pmc Prostate stem cells and benign prostatic hyperplasia
    John T Isaacs
    Department of Oncology, The Chemical Therapeutics Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Prostate 68:1025-34. 2008
    ....
  87. ncbi Epigenetic programming of the germ line: effects of endocrine disruptors on the development of transgenerational disease
    Matthew D Anway
    Centre for Reproductive Biology, School of Molecular Biosciences, Washington State University, Pullman, WA 99164 4231, USA
    Reprod Biomed Online 16:23-5. 2008
    ..The epigenetic mechanism involves the alteration of DNA methylation in the germ line that appears to transmit transgenerational adult onset disease, including spermatogenic defects, prostate disease, kidney disease and cancer...
  88. ncbi Effect of the anti-androgenic endocrine disruptor vinclozolin on embryonic testis cord formation and postnatal testis development and function
    Mehmet Uzumcu
    Center for Reproductive Biology, School of Molecular Biosciences, Washington State University, Pullman, WA 99164 4231, USA
    Reprod Toxicol 18:765-74. 2004
    ..Observations indicate that transient exposure to an anti-androgenic endocrine disruptor during embryonic development causes delayed effects later in adult life on spermatogenic capacity...
  89. ncbi Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413
    M Roach
    University of California San Francisco, 1600 Divisadero St, Suite H1031, San Francisco, CA 94143 1708, USA
    J Clin Oncol 21:1904-11. 2003
    ..This trial also tested the hypothesis that neoadjuvant and concurrent hormonal therapy (NCHT) improves PFS compared with adjuvant hormonal therapy (AHT) by 10%...
  90. ncbi Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon
    Jean Pierre Raynaud
    D R I T T, Universite Pierre et Marie Curie, 4 place Jussieu, Paris, France
    J Steroid Biochem Mol Biol 82:233-9. 2002
    ..The dual inhibitory activity of LSESr on 5alpha-reductase type 1 and type 2 can be attributed to its high content in free fatty acids...
  91. pmc Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, and Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX 77555 0562, USA
    Arch Intern Med 166:465-71. 2006
    ..We therefore sought to estimate the incidence of these effects and, by using a control group, ascertain whether these effects were related to androgen deprivation itself...
  92. ncbi Cognitive effects of hormone therapy in men with prostate cancer: a review
    Christian J Nelson
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Cancer 113:1097-106. 2008
    ....
  93. ncbi Transgenerational effects of the endocrine disruptor vinclozolin on the prostate transcriptome and adult onset disease
    Matthew D Anway
    Center for Reproductive Biology, School of Molecular Biosciences, Washington State University, Pullman, Washington 99164 4231, USA
    Prostate 68:517-29. 2008
    ..The ability of an endocrine disruptor exposure during gonadal sex determination to promote a transgenerational prostate disease phenotype was investigated in the current study...
  94. ncbi Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells
    Scott M Dehm
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 281:27882-93. 2006
    ..Our data thus demonstrate that the AR can inappropriately activate transcription in ADI PCa cells via mechanisms that are resistant to castration and AR antagonism, the two modes of androgen ablation used to treat advanced PCa...
  95. ncbi One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men
    Osvaldo P Almeida
    School of Psychiatry and Clinical Neurosciences, University of Western Australia, Mail Point M573 Level 6, Ainslie House, Royal Perth Hospital, 35 Stirling Highway, Perth, WA 6009, Australia
    Psychoneuroendocrinology 29:1071-81. 2004
    ..The performance of subjects on the WL test was negatively correlated with plasma levels of Abeta, but the clinical significance of this finding remains to be determined...
  96. ncbi Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial
    Susan L Greenspan
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Ann Intern Med 146:416-24. 2007
    ..Androgen deprivation therapy (ADT) in men with prostate cancer is associated with bone loss and fractures...
  97. ncbi Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
    J Clin Oncol 22:1025-33. 2004
    ..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy...
  98. ncbi Management of androgen-independent prostate cancer
    Michael Diaz
    Genitourinary Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 11:364-73. 2004
    ..Although androgen withdrawal can control prostate cancer for long periods in many patients, controversy exists regarding management when the tumor becomes androgen independent. Several options are now available...
  99. ncbi Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity
    Hiromitsu Kawata
    Pharmaceutical Research Department 2, Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, Kamakura, Kanagawa, Japan
    Prostate 70:745-54. 2010
    ..However, the mechanism of bicalutamide resistance remains unclear because few cell models have been generated...
  100. ncbi Saw palmetto for benign prostatic hyperplasia
    Stephen Bent
    Osher Center for Integrative Medicine, Department of Medicine, University of California, San Francisco, San Francisco, USA
    N Engl J Med 354:557-66. 2006
    ..Saw palmetto is used by over 2 million men in the United States for the treatment of benign prostatic hyperplasia and is commonly recommended as an alternative to drugs approved by the Food and Drug Administration...
  101. ncbi Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations
    Yan Shi
    Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    BJU Int 97:170-8. 2006
    ....

Research Grants67

  1. A Soft Topical Antiandrogenic Drug
    Wei Chu Xu; Fiscal Year: 2013
    ..However, the systemic antiandrogen side effects of marketed nonsteroidal androgen antagonists (flutamide, nilutamide, bicalutamide) and 5[unreadable]-reductase type 2 inhibitors (finasteride) are ..
  2. Mechanisms of Action and Signaling by Steroid Hormone Antagonists
    Douglas V Faller; Fiscal Year: 2013
    ..Estrogen antagonists and androgen antagonists comprise the most widely-used endocrine therapies for breast cancer and prostate cancer, respectively...
  3. ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy
    Matthew Smith; Fiscal Year: 2004
    ..In addition, this project will provide important insights into the relative contributions of testosterone and estrogen in bone metabolism, and maintenance of muscle size and strength in older men. ..
  4. MOLECULAR RECOGNITION IN STEROID SIGNALING
    Fraydoon Rastinejad; Fiscal Year: 2002
    ..This receptor specifically binds both steroid and non-steroid androgen antagonists used for the treatment of prostate cancer...
  5. Mechanisms of Resistant Prostate Cancer
    Amir Gamliel; Fiscal Year: 2006
    ..Virtually all-prostate cancers become androgen-independent and androgen antagonists are converted to agonists...
  6. Managed Care Penetration and Cancer Care
    Nancy Keating; Fiscal Year: 2003
    ..If managed care penetration is negatively associated with the delivery of care, interventions targeted toward policy-makers, providers, and patients will be needed to counteract the effects of market forces. ..
  7. Local Therapy of Breast Cancer in Community Populations
    Nancy Keating; Fiscal Year: 2007
    ..Moreover, the work will provide insight into different techniques for the analysis of observational data. ..
  8. Fractures, Heart Disease, and Stroke on Aromatase Inhibitors
    Nancy L Keating; Fiscal Year: 2010
    ....
  9. Acupuncture for hot flashes in prostate cancer patients
    TOMASZ BEER; Fiscal Year: 2004
    ..The overall goal is to provide prostate cancer patients an effective, low toxicity, non-pharmacologic treatment modality for hot flashes. ..
  10. A Novel Vitamin D Target in Human Prostate Cancer
    TOMASZ BEER; Fiscal Year: 2007
    ..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. [unreadable] [unreadable]..
  11. Oregon Prostate Cancer Conference 2001
    TOMASZ BEER; Fiscal Year: 2003
    ....
  12. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2009
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  13. Optimizing use of androgen deprivation therapy for prostate cancer
    Vahakn B Shahinian; Fiscal Year: 2010
    ..POP dominant) on care of men on ADT. ..
  14. GnRH Agonists For Prostate Cancer: Role of the Urologist
    Vahakn Shahinian; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  15. Xenogen IVIS-200 Bioluminescent Imaging System
    Alan Pollack; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  16. Cognitive Effects of Opioids in Older Adults
    Monique Cherrier; Fiscal Year: 2006
    ..abstract_text> ..
  17. Testosterone Supplementation in Men with MCI
    Monique Cherrier; Fiscal Year: 2009
    ..Further, results of this study will provide valuable information for planning, larger future trials of T supplementation or selective androgen receptor modulators (SARMs). ..
  18. Targeting of the Androgen Receptor in Prostate Cancer
    John Isaacs; Fiscal Year: 2005
    ..These peptide prodrugs will be designed so that they are substrates for the enzymatic activity of either Prostate Specific Antigen. ..
  19. TUMT verses Medical Therapy in Treatment of BPH
    E Crawford; Fiscal Year: 2005
    ..The PI has enlisted the support of consultants who will assist in this important evaluation. The results of this analysis will be critical in allocating health care resources. ..
  20. Breast Cancer Screening and Follow-up in a PBRN: The Ma*
    Michael Barry; Fiscal Year: 2007
    ..We will create a process to track all patients within our PBRN and to reduce current barriers to ordering and following up of abnormal mammogram results. [unreadable] [unreadable]..
  21. Prenatal development, spatial ability, and hippocampus
    Rebecca Herman; Fiscal Year: 2004
    ..abstract_text> ..
  22. PROSTATE CANCER SCREENING & MORTALITY: SEATTLE VS. CT.
    Michael Barry; Fiscal Year: 2004
    ....
  23. Hot Flashes and Anxiety Sensitivity Among Breast Cancer Survivors
    Laura Hanisch; Fiscal Year: 2008
    ..The goal is to develop better strategies for the self-management of hot flashes using cognitive-behavioral techniques. [unreadable] [unreadable] [unreadable]..
  24. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2003
    ..abstract_text> ..
  25. Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for Ca
    Samuel R Denmeade; Fiscal Year: 2010
    ..e. "stroma") within cancers rather than the cancer cells themselves can be effective therapy. The FAP- activated prodrug, therefore, could represent a new targeted therapy for a variety of human cancers. ..
  26. Group and Individual Differences in Audition
    Dennis McFadden; Fiscal Year: 2010
    ..If so, theory, diagnosis, treatment, and nosology for ADHD could be affected. ..
  27. Systematic Reviews in Urologic Diseases
    Timothy Wilt; Fiscal Year: 2008
    ..This will provide rapid dissemination, enhances implementation, and identifies new areas requiring additional research. ..
  28. Effects of Male Vocalizations on Long-Term Pair Bonds
    Michelle Tomaszycki; Fiscal Year: 2004
    ..These findings will contribute to an understanding of the importance of vocal communication in the formation and maintenance of social relationships in animals. ..
  29. Estrogen regulation of osteoclastogenesis in older men
    Pamela Taxel; Fiscal Year: 2003
    ..abstract_text> ..
  30. Radiation, Hormones & Antisense Prostate Cancer Therapy
    Alan Pollack; Fiscal Year: 2007
    ..abstract_text> ..
  31. Role of BAF57 in AR control and prostate cancer growth
    Karen E Knudsen; Fiscal Year: 2010
    ..Together, these studies will reveal the efficacy of BAF57 as a therapeutic target in both early and late stage prostate cancer. ..
  32. Bis-phenol A: Signaling and Mitogenesis in the Prostate
    Karen Knudsen; Fiscal Year: 2006
    ..abstract_text> ..
  33. Coactivators and Androgen Receptors in Prostate Cancer
    NANCY WEIGEL; Fiscal Year: 2006
    ..abstract_text> ..
  34. Photoperiod, melatonin, and reproductive aging
    NED PLACE; Fiscal Year: 2008
    ..Once the objectives of this award have been met, the candidate will work as an independent investigator, and carry out research on reproductive aging that is truly integrative. ..
  35. Molecular Defects of Insulin Signaling in PCOS
    Ricardo Azziz; Fiscal Year: 2004
    ..Long term, these studies have the potential of eventually elucidating the etiologic mechanism(s) in some, or most, patients; helping to develop targeted therapies; and guiding the search for molecular markers for PCOS. ..
  36. Foward Genetic Study of Surface Coat Genes Expression in Trypanosoma Brucei
    Gwo Shu Lee; Fiscal Year: 2008
    ..The success of this study may lead to potential targets for therapeutic designs via intervention of essential processes involved in the switching of VSG gene expression. [unreadable] [unreadable] [unreadable]..
  37. Androgens and Alzheimer's Disease
    Christian Pike; Fiscal Year: 2009
    ..Together, we believe these novel and timely studies will begin an important evaluation of interactions between normal male aging events, neuroprotection, A-beta regulation, and the risk of developing Alzheimer's disease. ..
  38. FEMALE SEXUAL AROUSAL: CLITORAL AND VAGINAL PHYSIOLOGY
    Abdulmaged Traish; Fiscal Year: 2003
    ....
  39. BEHAVIORAL DEVELOPMENT--PRENATAL HORMONAL INFLUENCES
    Kim Wallen; Fiscal Year: 2002
    ..The combination of these efforts will allow the PI to expand his research into new areas, while increasing his understanding of its relevance to important human mental health conditions. ..
  40. Population-Based Reference Ranges for Testosterone
    VASAN S RAMACHANDRAN; Fiscal Year: 2010
    ..These steps will facilitate the development of rational criteria for classifying men into androgen-deficient and androgen-replete categories. ..
  41. EXERCISE EFFECTS ON QUALITY OF LIFE IN CANCER PATIENTS
    Kerry Courneya; Fiscal Year: 2001
    ..Fitness will be re-assessed immediately after the intervention period. ..
  42. GORDON CONFERENCE ON ENVIRONMENTAL ENDOCRINE DISRUPTORS
    ANA SOTO; Fiscal Year: 2002
    ..abstract_text> ..
  43. FREE PLASMA SEX HORMONE AND ANDROGEN ACTION
    Robert Rosenfield; Fiscal Year: 2001
    ....
  44. NOVEL RADIOTRACERS FOR ANDROGEN RECEPTOR IMAGING
    MARCIAN VAN DORT; Fiscal Year: 2001
    ..abstract_text> ..
  45. Atherosclerosis Stage, Estrogen Receptors, and Vascular Responses to Estrogen
    THOMAS COSTIN REGISTER; Fiscal Year: 2010
    ....
  46. CELL CELL INTERACTIONS IN PROSTATE CANCER
    Gerald Cunha; Fiscal Year: 2001
    ..These studies should define critical cellular and molecular pathways in both normal and tumorigenic growth of the prostate, and should provide the biological basis of new therapeutic strategies. ..
  47. Development Estrogenization of the Rat Prostate Gland
    Gail S Prins; Fiscal Year: 2010
    ..Results will further define the mechanisms of estrogen's actions on the prostate gland during early development and lead to a better understanding of the hormonal and developmental basis for abnormal prostate growth with aging...
  48. TRANSCIPTION OF PROTEIN CODING GENES IN T BRUCE
    Gwo Shu Lee; Fiscal Year: 2001
    ..abstract_text> ..
  49. Action of Hormones on Protein and RNA Metabolism
    Michael McPhaul; Fiscal Year: 2004
    ..abstract_text> ..
  50. Androgens and molecular mediators of motoneuron repair
    KEITH FARGO; Fiscal Year: 2008
    ..This research could potentially lead to future treatment strategies for traumatic nerve injuries and neurodegenerative diseases. [unreadable] [unreadable]..
  51. 2007 AUA/SBUR Summer Research Conference "Clinical Trials and Outcomes Research"
    David Penson; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  52. SPIRIT:Reproductive Peer Counseling for Breast Cancer
    Leslie Schover; Fiscal Year: 2006
    ..In addition, we will conduct 50 semi-structured, qualitative phone interviews with survivors diagnosed under age 45, to better identify and characterize concerns of this young, at-risk group. ..
  53. Crystal Farm Imaging System
    Robert Fletterick; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  54. REGULATION OF ORPHAN NUCLEAR RECEPTORS LRH-1 AND SF-1
    Robert Fletterick; Fiscal Year: 2005
    ..The studies proposed in this grant application would provide the means for developing selective therapeutics tuning the aberrant transcriptional activity of these nuclear receptors. ..
  55. A State-of-the-art BIACORE for UCSF Mission Bay
    Robert Fletterick; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  56. P-Glycoprotein and Disposition of Psychostimulants
    JOHN MARKOWITZ; Fiscal Year: 2005
    ....
  57. Mechanistic bases for age-related androgen deficiency
    Johannes Veldhuis; Fiscal Year: 2007
    ..Knowing why testosterone falls should help foster new and safer ways to prevent the problem. [unreadable] [unreadable] [unreadable]..
  58. PREDOCTORAL TRAINING PROGRAM IN NEUROSCIENCE
    RALPH FREGOSI; Fiscal Year: 2008
    ..Facilities for research training include the extensive equipment and expertise in individual faculty laboratories, as well as comprehensive shared resources at the University of Arizona. ..
  59. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2003
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  60. Neuroactive Steroid Therapy of Catamenial Epilepsy
    DOODIPALA REDDY; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  61. Role of Prohibitin in Mediating Suppression of Breast Cancer Growth by Estrogen *
    Sheng Wang; Fiscal Year: 2004
    ..abstract_text> ..
  62. Immunobiological Role of Fertilization Antigen(FA-1)
    RAJESH NAZ; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  63. Ensemble Disruption of the GnRH-LH-Testosterone Axis
    Johannes Veldhuis; Fiscal Year: 2007
    ..Expected corollary outcomes are enhanced diagnosis, assessment and management of more subtle pathophysiology of the male gonadal axis in puberty and adulthood. ..
  64. Cognitive Consequences of Endocrine Dysfunction in IDU
    Adrian Dobs; Fiscal Year: 2007
    ..We will obtain a better understanding of the relationship between drug use and cognition, and also expand our understanding of the effects of sex steroids on cognitive performance, in an under-studied population. ..
  65. Testosterone:Physical Function in Men on Hemodialysis
    Shalender Bhasin; Fiscal Year: 2004
    ..Therefore, if successful, this study should help identify a therapeutic intervention that might improve physical function and reduce disability in men with end stage renal disease. ..